Cargando…

Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) displays sex-biased incidence, outcomes, molecular alterations and treatment efficacy; however, clinical managements are largely identical in male and female patients. Moreover, many biomarkers have been identified as predictors for ccRCC outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Huiyang, Qin, Xin, Yang, Qingya, Liu, Li, Fang, Zhiqing, Fan, Yidong, Xu, Dawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334619/ https://www.ncbi.nlm.nih.gov/pubmed/37434223 http://dx.doi.org/10.1186/s13293-023-00526-7

Ejemplares similares

The chromosomal instability 25 gene signature is identified in clear cell renal cell carcinoma and serves as a predictor for survival and Sunitinib response
por: Wang, Chang, et al.
Publicado: (2023)

The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma
por: Yuan, Huiyang, et al.
Publicado: (2022)

Inhibition of telomerase RNA decay rescues telomerase deficiency caused by dyskerin or PARN defects
por: Shukla, Siddharth, et al.
Publicado: (2016)

SMN and coilin negatively regulate dyskerin association with telomerase RNA
por: Poole, Aaron R., et al.
Publicado: (2016)

Relationship between Dyskerin Expression and Telomerase Activity in Human Breast Cancer
por: Montanaro, Lorenzo, et al.
Publicado: (2008)

Native gel electrophoresis of human telomerase distinguishes active complexes with or without dyskerin
por: Gardano, Laura, et al.
Publicado: (2012)

GSE4, a Small Dyskerin- and GSE24.2-Related Peptide, Induces Telomerase Activity, Cell Proliferation and Reduces DNA Damage, Oxidative Stress and Cell Senescence in Dyskerin Mutant Cells
por: Iarriccio, Laura, et al.
Publicado: (2015)

Genomic, epigenomic, and transcriptomic signatures for telomerase complex components: a pan‐cancer analysis
por: Wang, Jing, et al.
Publicado: (2022)

Single-Molecule Analysis of the Human Telomerase RNA·Dyskerin Interaction and the Effect of Dyskeratosis Congenita Mutations
por: Ashbridge, Beth, et al.
Publicado: (2009)

Discovery of new chromen-4-one derivatives as telomerase inhibitors through regulating expression of dyskerin
por: Quan Wang, Jie, et al.
Publicado: (2018)

N-terminal residues of human dyskerin are required for interactions with telomerase RNA that prevent RNA degradation
por: MacNeil, Deanna E, et al.
Publicado: (2019)

Sex differences in telomere length, lifespan, and embryonic dyskerin levels
por: Lansdorp, Peter M.
Publicado: (2022)

Homology Model and Docking-Based Virtual Screening for Ligands of Human Dyskerin as New Inhibitors of Telomerase for Cancer Treatment
por: Armando, Romina Gabriela, et al.
Publicado: (2018)

Drosophila dyskerin is required for somatic stem cell homeostasis
por: Vicidomini, Rosario, et al.
Publicado: (2017)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Shibasaki, Noboru, et al.
Publicado: (2015)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma
por: Nagase, Kei, et al.
Publicado: (2021)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer
por: Stewart, Grant D., et al.
Publicado: (2016)

Dyskerin Localizes to the Mitotic Apparatus and Is Required for Orderly Mitosis in Human Cells
por: Alawi, Faizan, et al.
Publicado: (2013)

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
por: Maroto, P, et al.
Publicado: (2017)

Nomograms for predicting long-term overall survival and disease-specific survival of patients with clear cell renal cell carcinoma
por: Zhang, Guanghao, et al.
Publicado: (2018)

Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib
por: Zheng, Wan-Xiang, et al.
Publicado: (2015)

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
por: Kontovinis, Loukas F, et al.
Publicado: (2009)

Acute Acalculous Cholecystitis in Patients With Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Report of Two Cases
por: Furubayashi, Nobuki, et al.
Publicado: (2014)

Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
por: Pilskog, Martin, et al.
Publicado: (2017)

Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma
por: Peng, Qiang, et al.
Publicado: (2019)

TFE3‐PD‐L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma
por: Guo, Xudong, et al.
Publicado: (2020)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Wei, Yuang, et al.
Publicado: (2021)

Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma
por: Song, Zhengshuai, et al.
Publicado: (2020)

A functional connection between dyskerin and energy metabolism
por: Angrisani, Alberto, et al.
Publicado: (2017)

A new role for human dyskerin in vesicular trafficking
por: Di Maio, Nunzia, et al.
Publicado: (2017)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2018)

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021)

miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma
por: Park, Sang Eun, et al.
Publicado: (2022)

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
por: Alifrangis, C, et al.
Publicado: (2016)

Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma
por: Huang, Wan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8eaa5kcvkpqq112nnve600veb3